Sellas Life Sciences Group Inc (SLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2025 | 12-2024 | 09-2024 | 06-2024 | 03-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 28,497 | 13,986 | 21,131 | 9,247 | 18,515 |
| TOTAL | $31,973 | $16,327 | $24,035 | $12,302 | $21,501 |
| Non-Current Assets | |||||
| Intangibles | 1,914 | 1,914 | 1,914 | 1,914 | 1,914 |
| Other Non-Current Assets | 1,069 | 1,191 | 556 | 903 | 1,019 |
| TOTAL | $2,983 | $3,105 | $2,470 | $2,817 | $2,933 |
| Total Assets | $34,956 | $19,432 | $26,505 | $15,119 | $24,434 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 3,756 | 3,500 | 4,547 | 6,331 | 7,407 |
| Accrued Expenses | 2,571 | 5,466 | 5,490 | 5,183 | 6,542 |
| TOTAL | $6,888 | $9,510 | $10,613 | $12,045 | $14,437 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 309 | 457 | 0 | 161 | 313 |
| TOTAL | $309 | $457 | $N/A | $161 | $313 |
| Total Liabilities | $7,197 | $9,967 | $10,613 | $12,206 | $14,750 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 99,777 | 90,847 | 70,382 | 64,333 | 57,755 |
| Common Shares | 9 | 7 | 6 | 5 | 5 |
| Retained earnings | -253,938 | -248,125 | -241,388 | -234,280 | -226,810 |
| TOTAL | $27,759 | $9,465 | $15,892 | $2,913 | $9,684 |
| Total Liabilities And Equity | $34,956 | $19,432 | $26,505 | $15,119 | $24,434 |